APO RESEARCH · REPORT
Age Related Macular Degeneration Drug
Age-related macular degeneration (AMD) is a disease that blurs the sharp, central vision you need for “straight-ahead” activities such as reading, sewing, and driving. AMD affects the macula, the part of the eye that allows you to see fine detail.
Product & engineering
Understand the product.
Age-related macular degeneration (AMD) is a disease that blurs the sharp, central vision you need for “straight-ahead” activities such as reading, sewing, and driving. AMD affects the macula, the part of the eye that allows you to see fine detail.
Selected research
Industry Research
Age Related Macular Degeneration Drug Industry Research Report 2026
Market perspective
Age-related macular degeneration (AMD) is a disease that blurs the sharp, central vision you need for “straight-ahead” activities such as reading, sewing, and driving. AMD affects the macula, the part of the eye that allows you to see fine detail.
North America is the largest Age Related Macular Degeneration Drug market with about 65% market share. Europe is follower, accounting for about 29% market share.
The key players are Regeneron Pharmaceuticals, Bayer HealthCare, Novartis, Roche, Kanghong Pharma etc. Top 3 companies occupied about 79% market share.
Read the full market overview
Report Scope
This report quantifies the global Age Related Macular Degeneration Drug market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Age Related Macular Degeneration Drug Market by Company
Regeneron Pharmaceuticals
Bayer HealthCare
Novartis
Roche
Kanghong Pharma
Age Related Macular Degeneration Drug Segment by Type
Lucentis
Eylea
Avastin
Others
Age Related Macular Degeneration Drug Segment by Application
Hospitals
Clinics
Others
Age Related Macular Degeneration Drug Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Age Related Macular Degeneration Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Age Related Macular Degeneration Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Age Related Macular Degeneration Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Age Related Macular Degeneration Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Age Related Macular Degeneration Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Age Related Macular Degeneration Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Lucentis
- Eylea
- Avastin
- Others
Applications
- Hospitals
- Clinics
- Others
Companies covered
- Regeneron Pharmaceuticals
- Bayer HealthCare
- Novartis
- Roche
- Kanghong Pharma
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Age Related Macular Degeneration Drug Market Size (2021-2032)
- 2.2.2 Global Age Related Macular Degeneration Drug Sales (2021-2032)
- 2.2.3 Global Age Related Macular Degeneration Drug Market Average Price (2021-2032)
- 2.3 Age Related Macular Degeneration Drug by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Lucentis
- 2.3.3 Eylea
- 2.3.4 Avastin
- 2.3.5 Others
- 2.4 Age Related Macular Degeneration Drug by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospitals
- 2.4.3 Clinics
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Age Related Macular Degeneration Drug Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Age Related Macular Degeneration Drug Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Age Related Macular Degeneration Drug Revenue of Manufacturers (2021-2026)
- 3.4 Global Age Related Macular Degeneration Drug Average Price by Manufacturers (2021-2026)
- 3.5 Global Age Related Macular Degeneration Drug Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Age Related Macular Degeneration Drug, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Age Related Macular Degeneration Drug, Product Type & Application
- 3.8 Global Manufacturers of Age Related Macular Degeneration Drug, Established Date
- 3.9 Global Age Related Macular Degeneration Drug Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Regeneron Pharmaceuticals
- 4.1.1 Regeneron Pharmaceuticals Company Information
- 4.1.2 Regeneron Pharmaceuticals Business Overview
- 4.1.3 Regeneron Pharmaceuticals Age Related Macular Degeneration Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Regeneron Pharmaceuticals Age Related Macular Degeneration Drug Product Portfolio
- 4.1.5 Regeneron Pharmaceuticals Recent Developments
- 4.2 Bayer HealthCare
- 4.2.1 Bayer HealthCare Company Information
- 4.2.2 Bayer HealthCare Business Overview
- 4.2.3 Bayer HealthCare Age Related Macular Degeneration Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Bayer HealthCare Age Related Macular Degeneration Drug Product Portfolio
- 4.2.5 Bayer HealthCare Recent Developments
- 4.3 Novartis
- 4.3.1 Novartis Company Information
- 4.3.2 Novartis Business Overview
- 4.3.3 Novartis Age Related Macular Degeneration Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Novartis Age Related Macular Degeneration Drug Product Portfolio
- 4.3.5 Novartis Recent Developments
- 4.4 Roche
- 4.4.1 Roche Company Information
- 4.4.2 Roche Business Overview
- 4.4.3 Roche Age Related Macular Degeneration Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Roche Age Related Macular Degeneration Drug Product Portfolio
- 4.4.5 Roche Recent Developments
- 4.5 Kanghong Pharma
- 4.5.1 Kanghong Pharma Company Information
- 4.5.2 Kanghong Pharma Business Overview
- 4.5.3 Kanghong Pharma Age Related Macular Degeneration Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Kanghong Pharma Age Related Macular Degeneration Drug Product Portfolio
- 4.5.5 Kanghong Pharma Recent Developments
5 Global Age Related Macular Degeneration Drug Market Scenario by Region
- 5.1 Global Age Related Macular Degeneration Drug Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Age Related Macular Degeneration Drug Sales by Region: 2021-2032
- 5.2.1 Global Age Related Macular Degeneration Drug Sales by Region: 2021-2026
- 5.2.2 Global Age Related Macular Degeneration Drug Sales by Region: 2027-2032
- 5.3 Global Age Related Macular Degeneration Drug Revenue by Region: 2021-2032
- 5.3.1 Global Age Related Macular Degeneration Drug Revenue by Region: 2021-2026
- 5.3.2 Global Age Related Macular Degeneration Drug Revenue by Region: 2027-2032
- 5.4 North America Age Related Macular Degeneration Drug Market Facts & Figures by Country
- 5.4.1 North America Age Related Macular Degeneration Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Age Related Macular Degeneration Drug Sales by Country (2021-2032)
- 5.4.3 North America Age Related Macular Degeneration Drug Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Age Related Macular Degeneration Drug Market Facts & Figures by Country
- 5.5.1 Europe Age Related Macular Degeneration Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Age Related Macular Degeneration Drug Sales by Country (2021-2032)
- 5.5.3 Europe Age Related Macular Degeneration Drug Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Age Related Macular Degeneration Drug Market Facts & Figures by Country
- 5.6.1 Asia Pacific Age Related Macular Degeneration Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Age Related Macular Degeneration Drug Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Age Related Macular Degeneration Drug Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Age Related Macular Degeneration Drug Market Facts & Figures by Country
- 5.7.1 South America Age Related Macular Degeneration Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Age Related Macular Degeneration Drug Sales by Country (2021-2032)
- 5.7.3 South America Age Related Macular Degeneration Drug Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Age Related Macular Degeneration Drug Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Age Related Macular Degeneration Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Age Related Macular Degeneration Drug Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Age Related Macular Degeneration Drug Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Age Related Macular Degeneration Drug Sales by Type (2021-2032)
- 6.1.1 Global Age Related Macular Degeneration Drug Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Age Related Macular Degeneration Drug Sales Market Share by Type (2021-2032)
- 6.2 Global Age Related Macular Degeneration Drug Revenue by Type (2021-2032)
- 6.2.1 Global Age Related Macular Degeneration Drug Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Age Related Macular Degeneration Drug Revenue Market Share by Type (2021-2032)
- 6.3 Global Age Related Macular Degeneration Drug Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Age Related Macular Degeneration Drug Sales by Application (2021-2032)
- 7.1.1 Global Age Related Macular Degeneration Drug Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Age Related Macular Degeneration Drug Sales Market Share by Application (2021-2032)
- 7.2 Global Age Related Macular Degeneration Drug Revenue by Application (2021-2032)
- 7.2.1 Global Age Related Macular Degeneration Drug Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Age Related Macular Degeneration Drug Revenue Market Share by Application (2021-2032)
- 7.3 Global Age Related Macular Degeneration Drug Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Age Related Macular Degeneration Drug Value Chain Analysis
- 8.1.1 Age Related Macular Degeneration Drug Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Age Related Macular Degeneration Drug Production Mode & Process
- 8.2 Age Related Macular Degeneration Drug Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Age Related Macular Degeneration Drug Distributors
- 8.2.3 Age Related Macular Degeneration Drug Customers
9 Global Age Related Macular Degeneration Drug Analyzing Market Dynamics
- 9.1 Age Related Macular Degeneration Drug Industry Trends
- 9.2 Age Related Macular Degeneration Drug Industry Drivers
- 9.3 Age Related Macular Degeneration Drug Industry Opportunities and Challenges
- 9.4 Age Related Macular Degeneration Drug Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst